Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Mounjaro (tirzepatide) is a prescription injectable medication FDA-approved in May 2022 for type 2 diabetes, manufactured by Eli Lilly. It is the first and only dual GIP/GLP-1 receptor agonist.
In clinical trials, Mounjaro achieved average A1C reductions of 2.0–2.3% and weight loss of 15–25 pounds. Up to 50% of patients reached non-diabetic A1C levels.
Its sister drug Zepbound contains the same active ingredient but is approved for weight management.
Medfinder helps you locate pharmacies with Mounjaro in stock.
Mounjaro is a dual GIP/GLP-1 receptor agonist that mimics two hormones involved in blood sugar regulation and appetite control. GLP-1 activation stimulates insulin release and slows gastric emptying. GIP activation enhances these effects and may benefit fat metabolism.
Effects on blood sugar are noticeable within 1–2 weeks, with maximum A1C reduction after 12–24 weeks.
Mounjaro is available as subcutaneous injection in single-dose pens and vials:
Injected once weekly. All patients start at 2.5 mg for 4 weeks, then increase to 5 mg. Doses may be increased by 2.5 mg increments every 4 weeks. Must be refrigerated until use.
Mounjaro (tirzepatide) is an injectable medication for type 2 diabetes that has seen unprecedented demand — largely driven by its significant weight loss effects. We've assigned it a findability score of 60 out of 100, meaning patients should expect moderate difficulty locating this medication depending on dose and location.
The FDA officially resolved the tirzepatide shortage in October 2024 and reaffirmed this decision in a December 2024 declaratory order. A federal court upheld the decision in May 2025. All six Mounjaro dose strengths (2.5mg through 15mg) are currently listed as available from Eli Lilly.
However, "resolved" doesn't mean every pharmacy has it on the shelf. The FDA has acknowledged that patients may still experience intermittent localized supply disruptions as the medication moves through the supply chain.
FDA enforcement deadlines for compounded tirzepatide passed in early 2025. An estimated up to 2 million patients were using compounded tirzepatide, many of whom are now transitioning to brand-name Mounjaro or Zepbound — adding pressure on pharmacy supply.
Mounjaro is not a controlled substance, so there are no DEA production quotas or pharmacy stocking limits. The main barriers are insurance coverage, cost, and local pharmacy stocking.
Medfinder can help you find Mounjaro in stock near you.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Mounjaro is not a controlled substance. Endocrinologists, PCPs, obesity medicine specialists, NPs, and PAs can prescribe it. Telehealth prescribing is available.
Medfinder helps you find pharmacies with availability.
No. Automatic refills, 90-day supplies, easy pharmacy transfers, and telehealth prescribing are all possible. The primary barriers are insurance coverage and cost.
Medfinder can help you find Mounjaro near you.
Boxed Warning: Thyroid C-cell tumor risk based on animal studies.
Medfinder can help you find Mounjaro near you.
Mounjaro is a breakthrough for type 2 diabetes as the first dual GIP/GLP-1 receptor agonist. The tirzepatide shortage is officially resolved, and Eli Lilly has massively expanded manufacturing. The main challenge is cost — Eli Lilly's savings card can reduce copays to $25/month for eligible patients.
Medfinder helps you find pharmacies with Mounjaro in stock. Search for availability near you.
%2C%20Color%3DOriginal.png)
.jpeg)
.jpeg)